Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02604407

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial

Official title:
A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Clinical Trial Summary

The study is designed to evaluate the efficacy and safety of each dose of SHP465 (12.5 and 37.5 mg) given to participants daily in the morning compared to placebo in the treatment of adults aged 18 to 55 years diagnosed with ADHD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Hyperkinesis
Clinical Trial Details
NCT number NCT02604407
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date November 19, 2015
Completion date March 24, 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT03260205 - Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) Phase 3
Withdrawn NCT03546400 - Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. Phase 4
Completed NCT02917109 - LearningRx Cognitive Training for ADHD N/A
Completed NCT02248948 - Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children N/A
Recruiting NCT01750307 - The Relationship of Essential Fatty Acids to Adult ADHD: The OCEAN Study (Oils and Cognitive Effects in Adult ADHD Neurodevelopment) N/A
Recruiting NCT06170996 - Internet-Assisted Behavioral Parent Training Intervention for Children With Attention Deficit Hyperactivity Disorder N/A
Completed NCT00735371 - Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 3
Withdrawn NCT03580005 - A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. Phase 4
Completed NCT02578030 - Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD Phase 1
Completed NCT02574273 - Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program) N/A
Completed NCT02257216 - Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD) N/A
Recruiting NCT04943796 - A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life
Recruiting NCT04634006 - Home-Based tDCS in Children With ADHD: A Randomized, Sham-Controlled tDCS and fNIRS Study N/A
Active, not recruiting NCT02908802 - Probiotic Supplement as Treatment for Students With ADHD N/A
Completed NCT05870605 - Drug Use Study With Intuniv® in European Countries
Terminated NCT03481959 - Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Phase 3
Terminated NCT03638466 - Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder Phase 2
Completed NCT03709940 - Brain Connectivity in Attention Deficit Hyperactivity Disorder (ADHD) N/A
Completed NCT02795637 - Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction Phase 1
Completed NCT01533493 - Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study N/A